Lipinski viie reegel (Estonian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lipinski viie reegel" in Estonian language version.

refsWebsite

Global rank Estonian rank

7doi.org

2^nd place

16^th place

7worldcat.org

5^th place

76^th place

6nih.gov

4^th place

14^th place

2drugbank.com

low place

2sciencedirect.com

149^th place

130^th place

1ut.ee

8,317^th place

11^th place

1acs.org

1,248^th place

753^rd place

acs.org

pubs.acs.org

Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D. (1. juuni 2002). "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates". Journal of Medicinal Chemistry (inglise). 45 (12): 2615–2623. DOI:10.1021/jm020017n. ISSN 0022-2623.

doi.org

Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J. (15. jaanuar 1997). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. In Vitro Models for Selection of Development Candidates. 23 (1): 3–25. DOI:10.1016/S0169-409X(96)00423-1. ISSN 0169-409X.
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1. märts 2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. 46 (1–3): 3–26. DOI:10.1016/s0169-409x(00)00129-0. ISSN 0169-409X. PMID 11259830.
Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D. (1. juuni 2002). "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates". Journal of Medicinal Chemistry (inglise). 45 (12): 2615–2623. DOI:10.1021/jm020017n. ISSN 0022-2623.
Lipinski, Christopher A. (2004). "Lead- and drug-like compounds: the rule-of-five revolution". Drug Discovery Today. Technologies. 1 (4): 337–341. DOI:10.1016/j.ddtec.2004.11.007. ISSN 1740-6749. PMID 24981612.
Roskoski, Robert (2023). "Rule of five violations among the FDA-approved small molecule protein kinase inhibitors". Pharmacological Research. 191: 106774. DOI:10.1016/j.phrs.2023.106774. ISSN 1096-1186. PMID 37075870.
Ganesan, A. (2008). "The impact of natural products upon modern drug discovery". Current Opinion in Chemical Biology. 12 (3): 306–317. DOI:10.1016/j.cbpa.2008.03.016. ISSN 1367-5931. PMID 18423384.
Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I. (1. juuni 2016). "BDDCS, the Rule of 5 and drugability". Advanced Drug Delivery Reviews. 101: 89–98. DOI:10.1016/j.addr.2016.05.007. ISSN 1872-8294. PMC 4910824. PMID 27182629.

drugbank.com

go.drugbank.com

"Acyclovir". go.drugbank.com (inglise). Vaadatud 14. novembril 2023.
"Venetoclax". go.drugbank.com (inglise). Vaadatud 14. novembril 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1. märts 2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. 46 (1–3): 3–26. DOI:10.1016/s0169-409x(00)00129-0. ISSN 0169-409X. PMID 11259830.
Lipinski, Christopher A. (2004). "Lead- and drug-like compounds: the rule-of-five revolution". Drug Discovery Today. Technologies. 1 (4): 337–341. DOI:10.1016/j.ddtec.2004.11.007. ISSN 1740-6749. PMID 24981612.
Roskoski, Robert (2023). "Rule of five violations among the FDA-approved small molecule protein kinase inhibitors". Pharmacological Research. 191: 106774. DOI:10.1016/j.phrs.2023.106774. ISSN 1096-1186. PMID 37075870.
Ganesan, A. (2008). "The impact of natural products upon modern drug discovery". Current Opinion in Chemical Biology. 12 (3): 306–317. DOI:10.1016/j.cbpa.2008.03.016. ISSN 1367-5931. PMID 18423384.
Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I. (1. juuni 2016). "BDDCS, the Rule of 5 and drugability". Advanced Drug Delivery Reviews. 101: 89–98. DOI:10.1016/j.addr.2016.05.007. ISSN 1872-8294. PMC 4910824. PMID 27182629.

ncbi.nlm.nih.gov

Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I. (1. juuni 2016). "BDDCS, the Rule of 5 and drugability". Advanced Drug Delivery Reviews. 101: 89–98. DOI:10.1016/j.addr.2016.05.007. ISSN 1872-8294. PMC 4910824. PMID 27182629.

sciencedirect.com

Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J. (15. jaanuar 1997). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. In Vitro Models for Selection of Development Candidates. 23 (1): 3–25. DOI:10.1016/S0169-409X(96)00423-1. ISSN 0169-409X.
Neidle, Stephen (1. jaanuar 2012), Neidle, Stephen (toim), "9 - Design Principles for Quadruplex-binding Small Molecules", Therapeutic Applications of Quadruplex Nucleic Acids, Boston: Academic Press, lk 151–174, ISBN 978-0-12-375138-6, vaadatud 14. novembril 2023

ut.ee

dspace.ut.ee

Normak, Karl (2017). "GDNF mimeetikute GFR 1-RET aktiveerimise eksperimentaalne uurimine ja QSAR modelleerimine". TÜ Keemia instituut, bakalaureusetöö. Vaadatud 14.11.2023.

worldcat.org

Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J. (15. jaanuar 1997). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. In Vitro Models for Selection of Development Candidates. 23 (1): 3–25. DOI:10.1016/S0169-409X(96)00423-1. ISSN 0169-409X.
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1. märts 2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews. 46 (1–3): 3–26. DOI:10.1016/s0169-409x(00)00129-0. ISSN 0169-409X. PMID 11259830.
Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D. (1. juuni 2002). "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates". Journal of Medicinal Chemistry (inglise). 45 (12): 2615–2623. DOI:10.1021/jm020017n. ISSN 0022-2623.
Lipinski, Christopher A. (2004). "Lead- and drug-like compounds: the rule-of-five revolution". Drug Discovery Today. Technologies. 1 (4): 337–341. DOI:10.1016/j.ddtec.2004.11.007. ISSN 1740-6749. PMID 24981612.
Roskoski, Robert (2023). "Rule of five violations among the FDA-approved small molecule protein kinase inhibitors". Pharmacological Research. 191: 106774. DOI:10.1016/j.phrs.2023.106774. ISSN 1096-1186. PMID 37075870.
Ganesan, A. (2008). "The impact of natural products upon modern drug discovery". Current Opinion in Chemical Biology. 12 (3): 306–317. DOI:10.1016/j.cbpa.2008.03.016. ISSN 1367-5931. PMID 18423384.
Benet, Leslie Z.; Hosey, Chelsea M.; Ursu, Oleg; Oprea, Tudor I. (1. juuni 2016). "BDDCS, the Rule of 5 and drugability". Advanced Drug Delivery Reviews. 101: 89–98. DOI:10.1016/j.addr.2016.05.007. ISSN 1872-8294. PMC 4910824. PMID 27182629.